Hennion & Walsh Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $859K | Buy |
499,252
+132,477
| +36% | +$228K | 0.03% | 527 |
|
|
2025
Q1 | $1.22M | Buy |
366,775
+30,794
| +9% | +$103K | 0.05% | 427 |
|
|
2024
Q4 | $2.49M | Sell |
335,981
-15,468
| -4% | -$114K | 0.11% | 232 |
|
|
2024
Q3 | $3.3M | Sell |
351,449
-16,703
| -5% | -$157K | 0.15% | 172 |
|
|
2024
Q2 | $2.95M | Sell |
368,152
-39,277
| -10% | -$315K | 0.15% | 169 |
|
|
2024
Q1 | $6.04M | Buy |
407,429
+121,395
| +42% | +$1.8M | 0.32% | 58 |
|
|
2023
Q4 | $2.33M | Buy |
286,034
+105,539
| +58% | +$858K | 0.13% | 224 |
|
|
2023
Q3 | $821K | Sell |
180,495
-1,036
| -0.6% | -$4.71K | 0.05% | 407 |
|
|
2023
Q2 | $1.28M | Buy |
181,531
+1,043
| +0.6% | +$7.34K | 0.08% | 325 |
|
|
2023
Q1 | $1.1M | Buy |
180,488
+10,982
| +6% | +$67.1K | 0.07% | 341 |
|
|
2022
Q4 | $1.08M | Buy |
169,506
+77,253
| +84% | +$494K | 0.07% | 321 |
|
|
2022
Q3 | $884K | Buy |
92,253
+8,233
| +10% | +$78.9K | 0.06% | 359 |
|
|
2022
Q2 | $928K | Buy |
84,020
+35,303
| +72% | +$390K | 0.06% | 328 |
|
|
2022
Q1 | $811K | Buy |
48,717
+19,235
| +65% | +$320K | 0.04% | 394 |
|
|
2021
Q4 | $563K | Buy |
+29,482
| New | +$563K | 0.03% | 515 |
|